GlassScriptPhysician profile
Prashant Kanu Patel
NPI 1982693974
$2,611.74
in general payments reported to CMS, 2019-2025
27 companies · $498 in 2025
The $498 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $558 · 2020: $104 · 2021: $295 · 2022: $567 · 2023: $282 · 2024: $307 · 2025: $498.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $991 · Education: $96.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $991.39 |
| Education | $96.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $631.69 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $275.32 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $230.22 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $176.52 | 2019-2025 | Jardiance, Synjardy |
| Sanofi-Aventis U.S. LLC | $128.74 | 2019-2025 | |
| Amgen INC. | $124.28 | 2019-2025 | Krystexxa, Otezla, Repatha |
| Abbott Laboratories | $121.41 | 2022-2025 | Eterna, Freestyle Libre 2, Freestyle Libre 3 |
| Mannkind Corporation | $117.51 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $109.84 | 2019-2023 | Belsomra |
| Pfizer INC. | $85.16 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $80.96 | 2019-2024 | Farxiga |
| Dexcom, INC. | $67.31 | 2021-2025 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $63.41 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $50.93 | 2019-2022 | |
| Insulet Corporation | $49.40 | 2021-2025 | Omnipod |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $49.38 | 2019-2022 | |
| Allergan, INC. | $32.37 | 2019-2020 | |
| Organogenesis INC. | $30.00 | 2025 | Apligraf |
| Medtronic, INC. | $29.33 | 2021-2025 | Minimed 780g |
| E.R. Squibb & Sons, L.L.C. | $28.74 | 2022-2024 | Eliquis |
| Emd Serono, INC. | $26.36 | 2019-2020 | |
| Glaxosmithkline, LLC. | $22.45 | 2023 | Shingrix, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $20.38 | 2019 | |
| Phathom Pharmaceuticals, INC. | $19.78 | 2025 | Voquezna |
| Sunovion Pharmaceuticals INC. | $16.05 | 2022 | |
| Beta Bionics, INC. | $15.64 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Travere Therapeutics, INC. | $8.56 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prashant Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.